Contact Us
Drug Search Results
More Filters [+]

Elobixibat

Alternative Names: elobixibat
Latest Update: 2024-07-29
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: IBAT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Indonesia | Japan | Philippines

Approved Indications: None

Known Adverse Events: None

Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Elobixibat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Constipation

Phase 2: Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Constipation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT06436833

N/A

Recruiting

Constipation|Colorectal Cancer|Diarrhea|Abdominal Pain|Anemia|Weight Loss|Chronic Pain

2024-11-30

TANK-27

P4

Recruiting

Constipation

2023-06-30

22-Nr-049

P4

Terminated

Constipation

2023-03-03

JapicCTI-184007

N/A

Active

Constipation

2022-12-01

Recent News Events

Date

Type

Title

02/17/2024

PubMed

 Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure.

02/03/2024

PubMed

 Comparison of the efficacy and tolerability of elobixibat plus sodium picosulfate with magnesium citrate and split-dose 2-L polyethylene glycol with ascorbic acid for bowel preparation before outpatient colonoscopy: a study protocol for the multicentre, randomised, controlled E-PLUS trial.

01/28/2024

PubMed

 Identifying causative medications for agranulocytosis: A case report of an older adult with cerebral infarction.

09/13/2022

News Article

 Global Chronic Idiopathic Constipation Drugs Market Report (2022 to 2030) - Key Trends Driving Growth

09/07/2022

News Article

 Worldwide Chronic Idiopathic Constipation (CIC) Drugs Industry to 2030 - by Drug Type, Prescription Type and Region

07/18/2021

News Article

 Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand

11/05/2020

News Article

 Albireo Reports Q3 2020 Financial Results and Provides Business Update

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions